{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477869681
| IUPAC_name = 2-(3-chlorobenzo[b][1]benzothiepin-5-yl)oxy-''N'',''N''-dimethylethanamine
| image = Zotepine.svg
| width = 220
| image2 = Zotepine-optimized-ball-and-stick.png
| width2 = 250

<!--Clinical data-->
| tradename =  Zoleptil
| Drugs.com = {{drugs.com|international|zotepine}}
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 7-13% (Oral)<ref name = "DRUGDEX">Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Jun 25]. Greenwood Village, CO: Thomsen Healthcare; 2013.</ref>
| metabolism =  N-desmethylation to norzotepine (30-40%)<ref name = "DRUGDEX" />
| elimination_half-life =  13.7-15.9 hours, 12 hours (Norzotepine)<ref name = "DRUGDEX" />
| excretion =  17% (Urine)<ref name = "DRUGDEX" />

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 26615-21-4
| ATC_prefix = N05
| ATC_suffix = AX11
| PubChem = 5736
| IUPHAR_ligand = 103
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB09225
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5534
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = U29O83JAZW
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01321
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 32316
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 285802

<!--Chemical data-->
| C=18 | H=18 | Cl=1 | N=1 | O=1 | S=1
| molecular_weight = 331.86
| smiles = Clc2cc1C(/OCCN(C)C)=C\c3c(Sc1cc2)cccc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HDOZVRUNCMBHFH-UHFFFAOYSA-N
}}

'''Zotepine''' (brand names: '''Losizopilon''' <small>([[Japan|JP]])</small>, '''Lodopin''' <small>([[Indonesia|ID]], [[Japan|JP]])</small>, '''Setous''' <small>([[Japan|JP]])</small>, '''Zoleptil''' <small>([[Czech Republic|CZ]], [[Portugal|PT]], [[Turkey|TR]], [[United Kingdom|UK]]†)</small>; where † indicates a formulation that has been discontinued) is an [[atypical antipsychotic]] [[drug]] indicated for acute and chronic [[schizophrenia]]. It has been used in [[Germany]] since 1990 (although it has been discontinued in Germany) and [[Japan]] since 1982.

Zotepine is not approved for use in the United States, United Kingdom, Australia, Canada or New Zealand.<ref name = Martindale>{{cite web|title=Zotepine|date=16 August 2013|accessdate=2 November 2013|url=http://www.medicinescomplete.com/mc/martindale/current/2479-d.htm?|publisher=Royal Pharmaceutical Society of Great Britain|work=Martindale: The Complete Drug Reference}}</ref>

== Medical uses ==
Zotepine's primary use is as a treatment for schizophrenia<ref name = "BNF 58"/> although clinical trials have been conducted (with positive results) into its efficacy as an antimanic agent in patients with acute bipolar mania.<ref>{{cite journal|title=A single-blind, comparative study of zotepine versus haloperidol in combination with a mood stabilizer for patients with moderate-to-severe mania|journal=Psychiatry and Clinical Neurosciences|author1=Chan, HY |author2=Jou, SH |author3=Juang, YY |author4=Chang, CJ |author5=Chen, JJ |author6=Chen, CH |author7=Chiu, NY |date=April 2010|pmid=20447012|doi=10.1111/j.1440-1819.2010.02066.x|volume=64|issue=2|pages=162–169}}</ref><ref>{{cite journal|title=Antimanic effect of zotepine|journal=Clinical Therapeutics|year=1986|volume=8|issue=4|pages=406–414|pmid=3089626|author1=Harada, T |author2=Otsuki, S }}</ref><ref>{{cite journal|title=Zotepine loading in acute and severely manic patients: a pilot study|journal=Bipolar Disorders|date=October 2005|volume=7|issue=5|pages=471–476|author1=Amann, B |author2=Sterr, A |author3=Mergl, R |author4=Dittmann, S |author5=Seemüller, F |author6=Dobmeier, M |author7=Orth, M |author8=Schaefer, M |author9=Grunze, H |doi=10.1111/j.1399-5618.2005.00241.x|pmid=16176441}}</ref> In a 2013 study in a comparison of 15 antipsychotic drugs in effectivity in treating schizophrenic symptoms, zotepine demonstrated medium-strong effectivity. Less effective than [[clozapine]], slightly less effective than [[olanzapine]] and [[risperidone]], approximately as effective as [[paliperidone]], and slightly more effective than [[haloperidol]], [[quetiapine]], and [[aripiprazole]].<ref>{{cite journal|last1=Leucht|first1=Stefan|last2=Cipriani|first2=Andrea|last3=Spineli|first3=Loukia|last4=Mavridis|first4=Dimitris|last5=Örey|first5=Deniz|last6=Richter|first6=Franziska|last7=Samara|first7=Myrto|last8=Barbui|first8=Corrado|last9=Engel|first9=Rolf R|last10=Geddes|first10=John R|last11=Kissling|first11=Werner|last12=Stapf|first12=Marko Paul|last13=Lässig|first13=Bettina|last14=Salanti|first14=Georgia|last15=Davis|first15=John M|title=Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis|journal=The Lancet|date=September 2013|volume=382|issue=9896|pages=951–962|doi=10.1016/S0140-6736(13)60733-3}}</ref>

== Side effects ==
;Common<ref name = "DRUGDEX" /><ref name = "BNF 58">British National Formulary 58. British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009.</ref>
{{colbegin|4}}
* [[Tachycardia]]
* [[Hypotension]]
* [[Orthostatic hypotension]]
* [[Palpitations]]
* [[Hyperprolactinaemia]]
* Weight gain (produces a similar degree of weight gain to that seen with [[clozapine]] and [[olanzapine]] treatment)<ref name = "Lancet" />
* [[Somnolence]] (2nd highest effect size for causing sedation out of fifteen antipsychotics compared in a recent meta-analysis)<ref name = "Lancet">{{cite journal|title=Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis|journal=Lancet|date=September 2013|volume=382|issue=9896|pages=951–962|doi=10.1016/S0140-6736(13)60733-3|pmid=23810019|author1=Leucht, S |author2=Cipriani, A |author3=Spineli, L |author4=Mavridis, D |author5=Orey, D |author6=Richter, F |author7=Samara, M |author8=Barbui, C |author9=Engel, RR |author10=Geddes, JR |author11=Kissling, W |author12=Stapf, MP |author13=Lässig, B |author14=Salanti, G |author15=Davis, JM }}</ref>
* [[Extrapyramidal side effects]] [EPSE] (2nd largest odds ratio for causing EPSE out of fifteen antipsychotics compared in a recent meta-analysis, second only to haloperidol)<ref name = "Lancet" />
* Constipation
* [[Xerostomia]] (dry mouth)
* Blurred vision
* [[Hypersalivation]] (drooling)
* [[Mydriasis]]
* Anxiety
* Agitation
* Rhinitis
* [[Sexual dysfunction]]
* [[Dyspnoea]]
* Diarrhoea
* Influenza-like symptoms
* Cough
* Vertigo
* Confusion
* [[Dyspepsia]]
* Flushing dry skin
* [[Arthralgia]]
* [[Myalgia]]
* Acne
* [[Conjunctivitis]]
* [[Thrombocythaemia]]
{{colend}}

;Unknown Frequency<ref name = "DRUGDEX" /><ref name = "BNF 58" />
{{colbegin|3}}
* [[QT interval]] prolongation
* [[Hyperthermia]]
* [[Hypothermia]]
* Increased serum [[creatinine]]
* [[Hyperglycaemia]]
* [[Hypoglycaemia]]
* [[Hyperlipidaemia]]
* Thirst
* Urinary incontinence
{{colend}}

;Rare<ref name = "DRUGDEX" /><ref name = "BNF 58" />
{{colbegin|4}}
* [[Angle-closure glaucoma]]
* [[Agranulocytosis]]
* [[Neutropaenia]]
* [[Eosinophilia]]
* [[Leukocytopenia]]
* [[Hypoesthesia]]
* [[Anaemia]]
* [[Myoclonus]]
* [[muscle weakness|Myasthenia]]
* [[Alopecia]]
* [[Thrombocytopaenia]]
* [[Bradycardia]]
* [[Epistaxis]]
* Abdominal enlargement
* [[Deep vein thrombosis]]
* Paralytic [[ileus]]
* [[Leukopenia]]
* [[Tardive dyskinesia]]
* [[Neuroleptic malignant syndrome]]
* [[Laryngeal edema]]
* [[Urinary retention]]
* Depression
* [[Ataxia]]
* [[Amnesia]]
* Seizure (dose-dependent risk)<ref name = Martindale/>
* [[Metabolic syndrome]]
* [[Diabetes mellitus]] type II
* [[Cholestasis]]
* Increased liver enzymes
* Photosensitivity
* Exanthema
* Pruritus
* [[Hypouricemia]]
* [[Oedema]]
{{colend}}

== Pharmacology ==

===Pharmacodynamics===
The antipsychotic effect of zotepine is thought to be mediated through [[receptor antagonist|antagonist]] activity at [[dopamine receptor|dopamine]] and [[serotonin receptor]]s. Zotepine has a high [[affinity (pharmacology)|affinity]] for the [[D1 receptor|D<sub>1</sub>]] and [[D2 receptor|D<sub>2</sub> receptor]]s. It also affects the [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2C receptor|5-HT<sub>2C</sub>]], [[5-HT6 receptor|5-HT<sub>6</sub>]], and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]]s.<ref name=PDSP>{{cite web|title=PDSD Ki Database |date=12 January 2011 |accessdate=2 November 2013 |publisher=University of North Carolina |place=Chapel Hill (NC) |author=National Institute of Mental Health |url=http://pdsp.med.unc.edu/pdsp.php |deadurl=yes |archiveurl=https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php |archivedate=November 8, 2013 }}</ref> In addition, its active metabolite, norzotepine, serves as a potent [[norepinephrine reuptake inhibitor]].<ref>{{cite journal|title=Norzotepine, a Major Metabolite of Zotepine, Exerts Atypical Antipsychotic-Like and Antidepressant-Like Actions through Its Potent Inhibition of Norepinephrine Reuptake|journal=The Journal of Pharmacology and Experimental Therapeutics|volume=333|issue=3|date=June 2010|url=http://jpet.aspetjournals.org/content/333/3/772.full.pdf|doi=10.1124/jpet.110.166264|pmid=20223878|pages=772–781|author1=Shobo, M |author2=Kondo, Y |author3=Yamada, H |author4=Mihara, T |author5=Yamamoto, N |author6=Katsuoka, M |author7=Harada, K |author8=Ni, K |author9=Matsuoka, N }}</ref>

{| class="wikitable"
|-
! Macromolecule (Receptor or transporter protein) !! K<sub>i</sub> [nM]<ref name = PDSP/>
|-
| [[Serotonin transporter|SERT]] || 151
|-
| [[Norepinephrine transporter|NET]] || 530
|-
| [[Dopamine transporter|DAT]] || 3621
|-
| [[5-HT1A receptor|5-HT<sub>1A</sub>]] || 470.5
|-
| [[5-HT1B receptor|5-HT<sub>1B</sub>]] || 59.5
|-
| [[5-HT1D receptor|5-HT<sub>1D</sub>]] || 119
|-
| [[5-HT1E receptor|5-HT<sub>1E</sub>]] || 700
|-
| [[5-HT2A receptor|5-HT<sub>2A</sub>]] || 2.7
|-
| [[5-HT2C receptor|5-HT<sub>2C</sub>]] || 2.6
|-
| [[5-HT3 receptor|5-HT<sub>3</sub>]] || 472
|-
| [[5-HT5A receptor|5-HT<sub>5A</sub>]] || 29
|-
| [[5-HT6 receptor|5-HT<sub>6</sub>]] || 6
|-
| [[5-HT7 receptor|5-HT<sub>7</sub>]] || 12
|-
| [[Alpha-1A adrenergic receptor|α<sub>1A</sub>]] || 7

|-
| [[Alpha-1B adrenergic receptor|α<sub>1B</sub>]] || 5
|-
| [[Alpha-2A adrenergic receptor|α<sub>2A</sub>]] || 180
|-
| [[Alpha-2B adrenergic receptor|α<sub>2B</sub>]] || 5.35
|-
| [[Alpha-2C adrenergic receptor|α<sub>2C</sub>]] || 106
|-
| [[Muscarinic acetylcholine receptor M1|M<sub>1</sub>]] || 18
|-
| [[Muscarinic acetylcholine receptor M2|M<sub>2</sub>]] || 140
|-
| [[Muscarinic acetylcholine receptor M3|M<sub>3</sub>]] || 73
|-
| [[Muscarinic acetylcholine receptor M4|M<sub>4</sub>]] || 77
|-
| [[Muscarinic acetylcholine receptor M5|M<sub>5</sub>]] || 260
|-
| [[Dopamine D1 receptor|D<sub>1</sub>]] || 71
|-
| [[Dopamine D2 receptor|D<sub>2</sub>]] || 25
|-
| D<sub>2S</sub> || 5.4
|-
| D<sub>2L</sub> || 11
|-
| [[Dopamine D3 receptor|D<sub>3</sub>]] || 6.4
|-
| [[Dopamine D4 receptor|D<sub>4</sub>]] || 18
|-
| [[Dopamine D5 receptor|D<sub>5</sub>]] || 248
|-
| [[Histamine H1 receptor|H<sub>1</sub>]] || 3.21
|-
| [[Histamine H2 receptor|H<sub>2</sub>]] || 500
|-
| [[Histamine H4 receptor|H<sub>4</sub>]] || 1977
|}

== See also ==
* [[Dosulepin]]
* [[Noxiptyline]]
* [[Carbinoxamine]], [[diphenhydramine]], [[doxylamine]], and [[orphenadrine]] the termination chain is the same
* [[Toll-like receptor 4]] investigating probable antagonistic (antiinflammatory) property of several TCA based molecules

== References ==
{{reflist}}
* http://www.priory.com/focus11.htm
* https://web.archive.org/web/20040619085151/http://www.nyrdtc.nhs.uk/docs/nde/Zotepine.pdf -
* [http://di.m-pharma.co.jp/file/if/f_los.pdf LOSIZOPILON SUGAR-COATED TABLETS & FINE GRANULES]{{dead link|date=July 2016 |bot=InternetArchiveBot |fix-attempted=yes }} (PDF)
* [http://psychodoc.eek.jp/abare/gallery/lodopin1982.jpg ロドピン（ゾテピン） 1982年　精神神経学雑誌]

{{Antipsychotics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Monoamine reuptake inhibitors}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Atypical antipsychotics]]
[[Category:Dibenzothiepines]]
[[Category:Chloroarenes]]
[[Category:Ethers]]
[[Category:Norepinephrine reuptake inhibitors]]